GLP-1受体激动剂与FDA批准AUD药物在代谢功能障碍合并酒精使用障碍中的真实世界结局比较
一项斯坦福医疗中心2017-2025年的回顾性队列研究,纳入1946例代谢功能障碍(MetD)合并酒精使用障碍(AUD)患者,比较GLP-1受体激动剂(GLP-1RA)与纳曲酮、阿坎酸、双硫仑的结局。倾向评分匹配后,GLP-1RA与1年AUD复发率更低、BMI和HbA1c改善更显著相关,失代偿性肝硬化发生率呈下降趋势但无统计学意义,死亡率相似。
要点
- GLP-1RA与AUD合并MetD患者1年复发风险降低相关(IRR 0.55)。
- GLP-1RA组BMI和HbA1c改善优于FDA批准AUD药物。
- 失代偿性肝硬化风险呈下降趋势但未达统计学显著(HR 0.52,p=0.09)。
核心结论
- GLP-1RA可能改善MetD合并AUD患者的AUD复发率和代谢结局,优于FDA批准AUD药物。
- 肝脏结局改善趋势支持进一步前瞻性评估。
研究设计与样本
- 斯坦福医疗中心2017-2025年回顾性队列研究,共1946例同时诊断AUD和MetD的患者。
- 暴露组为GLP-1RA(司美格鲁肽或替尔泊肽)治疗≥6个月,对照组为FDA批准AUD药物(纳曲酮、阿坎酸、双硫仑)。
- 采用倾向评分匹配减少混杂因素,平均随访1341天。
主要发现
- GLP-1RA组1年AUD复发率更低:IRR 0.55(95%CI 0.42-0.73),p<0.01。
- GLP-1RA组BMI降低更显著:-1.3 vs -0.3,p=0.004。
- GLP-1RA组HbA1c改善更显著:-1.0 vs +0.1,p=0.02。
- 失代偿性肝硬化发生率呈下降趋势但无统计学意义:HR 0.52,p=0.09。
- 死亡率两组相似。
关键数值与推荐
- MetD定义包括肥胖(BMI>25)和/或T2DM史且HbA1c>5.7。
- 排除诊断后1年内有晚期肝病的患者。
临床怎么用
- 对于合并MetD的AUD患者,GLP-1RA可能作为改善复发和代谢结局的潜在选择。
- 需结合患者代谢状况个体化评估,肝脏获益尚需前瞻性研究确认。
局限性
- 回顾性队列设计,存在残余混杂可能。
- GLP-1RA组BMI更高、T2DM比例更高(66% vs 14%),尽管经倾向评分匹配。
- 肝脏结局差异未达统计学显著,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapies for MetD, including type 2 diabetes mellitus (T2DM) and obesity. Recent studies suggested potential beneficial effects of GLP-1RA to decrease addictive behaviours in AUD. We evaluated the outcomes of GLP-1RA therapy compared with FDA-approved pharmacotherapies for AUD, including naltrexone, acamprosate, and disulfiram, in patients with dual risk factors of MetD and AUD. METHODS: We conducted a retrospective cohort study of patients at Stanford Health Care (2017-2025). Eligible patients had a concurrent diagnosis of alcohol-related complications meeting criteria for AUD and MetD, including obesity (BMI > 25) and/or a history of T2DM with HbA1c > 5.7. Those with advanced liver disease within 1 year of diagnosis were excluded. Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD. Propensity score matching was employed to reduce the effects of confounding factors. RESULTS: In total, 1946 patients were diagnosed concurrently with AUD and MetD. Of them, 274 patients were exposed to GLP-1RA, 1272 to naltrexone, 232 to acamprosate, and 168 to disulfiram. Patients were followed for an average of 1341 days. Patients exposed to GLP-1RA had higher BMI (35.5 vs. 30.1) and more T2DM (66% vs. 14%). GLP-1RA therapy was associated with lower 1-year AUD relapse [IRR 0.55, 95% CI 0.42-0.73; p < 0.01], greater BMI reduction (-1.3 vs. -0.3; p = 0.004), and HbA1c improvement (-1.0 vs. +0.1; p = 0.02). The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09]. Mortality was similar. CONCLUSIONS: GLP-1RAs are a promising option for patients with concurrent MetD and AUD, improving relapse rates and metabolic outcomes compared with currently FDA-approved pharmacotherapies for AUD. Trends toward better liver outcomes support further prospective evaluation.
引用
- Gougol A, Kwo P, Pike W, et al. Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications. Aliment Pharmacol Ther. 2026. PMID: 41813606. doi:10.1111/apt.70596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。